These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

279 related articles for article (PubMed ID: 38022528)

  • 1. Determination of the target of monoclonal immunoglobulins: a novel diagnostic tool for individualized MGUS therapy, and prevention and therapy of smoldering and multiple myeloma.
    Hermouet S; Bigot-Corbel E; Harb J
    Front Immunol; 2023; 14():1253363. PubMed ID: 38022528
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Characteristics of MGUS and Multiple Myeloma According to the Target of Monoclonal Immunoglobulins, Glucosylsphingosine, or Epstein-Barr Virus EBNA-1.
    Bosseboeuf A; Mennesson N; Allain-Maillet S; Tallet A; Piver E; Decaux O; Moreau C; Moreau P; Lehours P; Mégraud F; Salle V; Bigot-Corbel E; Harb J; Hermouet S
    Cancers (Basel); 2020 May; 12(5):. PubMed ID: 32429322
    [No Abstract]   [Full Text] [Related]  

  • 3. Impact of viral hepatitis therapy in multiple myeloma and other monoclonal gammopathies linked to hepatitis B or C viruses.
    Rodríguez-García A; Mennesson N; Hernandez-Ibarburu G; Morales ML; Garderet L; Bouchereau L; Allain-Maillet S; Piver E; Marbán I; Rubio D; Bigot-Corbel E; Martínez-López J; Linares M; Hermouet S
    Haematologica; 2024 Jan; 109(1):272-282. PubMed ID: 37199121
    [TBL] [Abstract][Full Text] [Related]  

  • 4. SOHO State of the Art Updates and Next Questions: Diagnosis and Management of Monoclonal Gammopathy of Undetermined Significance and Smoldering Multiple Myeloma.
    Schmidt T; Gahvari Z; Callander NS
    Clin Lymphoma Myeloma Leuk; 2024 Oct; 24(10):653-664. PubMed ID: 38641486
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Development of a Multivariable Model to Predict the Need for Bone Marrow Sampling in Persons With Monoclonal Gammopathy of Undetermined Significance : A Cohort Study Nested in a Clinical Trial.
    Eythorsson E; Rognvaldsson S; Thorsteinsdottir S; Einarsson Long T; Reed ER; Sigurdardottir GA; Vidarsson B; Onundarson PT; Agnarsson BA; Sigurdardottir M; Olafsson I; Thorsteinsdottir I; Sveinsdottir SV; Sigurdsson F; Thordardottir AR; Palsson R; Indridason OS; Jonsson A; Gislason GK; Olafsson A; Sigurdsson J; Steingrimsdottir H; Hultcrantz M; Durie BGM; Harding S; Landgren O; Aspelund T; Love TJ; Kristinsson SY
    Ann Intern Med; 2024 Apr; 177(4):449-457. PubMed ID: 38560901
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Changing paradigms in diagnosis and treatment of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Ho M; Patel A; Goh CY; Moscvin M; Zhang L; Bianchi G
    Leukemia; 2020 Dec; 34(12):3111-3125. PubMed ID: 33046818
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Diagnosis and Management of Monoclonal Gammopathy and Smoldering Multiple Myeloma.
    Schmidt T; Callander N
    J Natl Compr Canc Netw; 2020 Dec; 18(12):1720-1729. PubMed ID: 33347744
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering myeloma (SMM): a practical guide to management.
    Maciocia N; Wechalekar A; Yong K
    Hematol Oncol; 2017 Dec; 35(4):432-439. PubMed ID: 27804161
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Monoclonal gammopathies of unknown significance and smoldering myeloma: Assessment and management of the elderly patients.
    González-Calle V; Mateos MV
    Eur J Intern Med; 2018 Dec; 58():57-63. PubMed ID: 29907380
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Diagnosis, risk stratification and management of monoclonal gammopathy of undetermined significance and smoldering multiple myeloma.
    van de Donk NW; Mutis T; Poddighe PJ; Lokhorst HM; Zweegman S
    Int J Lab Hematol; 2016 May; 38 Suppl 1():110-22. PubMed ID: 27161311
    [TBL] [Abstract][Full Text] [Related]  

  • 11. The effects of short-term, progressive exercise training on disease activity in smouldering multiple myeloma and monoclonal gammopathy of undetermined significance: a single-arm pilot study.
    Emery A; Moore S; Crowe J; Murray J; Peacock O; Thompson D; Betts F; Rapps S; Ross L; Rothschild-Rodriguez D; Arana Echarri A; Davies R; Lewis R; Augustine DX; Whiteway A; Afzal Z; Heaney J; Drayson MT; Turner JE; Campbell JP
    BMC Cancer; 2024 Feb; 24(1):174. PubMed ID: 38317104
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Population-based screening cohort study reveals no association between monoclonal gammopathy of undetermined significance (MGUS), smoldering multiple myeloma (SMM), multiple myeloma (MM), and alopecia.
    Sharma D; Ungar B; Adalsteinsson JA; Sigurdsson JK; Sharp K; Thorsteinsdóttir S; Rögnvaldsson S; Þórðardóttir ÁR; Viðarsson B; Önundarson PT; Agnarssond BA; Sigurðardóttird M; Þorsteinsdóttir I; Ólafsson Í; Eyþórsson E; Jónsson Á; Ólafsson A; Gíslason GK; Landgren O; Hulcrantz M; Durie BG; Harding S; Love TJ; Kristinsson SY
    Arch Dermatol Res; 2024 Sep; 316(9):627. PubMed ID: 39276205
    [No Abstract]   [Full Text] [Related]  

  • 13. Efficacy of Antiviral Treatment in Hepatitis C Virus (HCV)-Driven Monoclonal Gammopathies Including Myeloma.
    Rodríguez-García A; Linares M; Morales ML; Allain-Maillet S; Mennesson N; Sanchez R; Alonso R; Leivas A; Pérez-Rivilla A; Bigot-Corbel E; Hermouet S; Martínez-López J
    Front Immunol; 2021; 12():797209. PubMed ID: 35087522
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Addition of Rice Bran Arabinoxylan to Curcumin Therapy May Be of Benefit to Patients With Early-Stage B-Cell Lymphoid Malignancies (Monoclonal Gammopathy of Undetermined Significance, Smoldering Multiple Myeloma, or Stage 0/1 Chronic Lymphocytic Leukemia): A Preliminary Clinical Study.
    Golombick T; Diamond TH; Manoharan A; Ramakrishna R
    Integr Cancer Ther; 2016 Jun; 15(2):183-9. PubMed ID: 27154182
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM): novel biological insights and development of early treatment strategies.
    Korde N; Kristinsson SY; Landgren O
    Blood; 2011 May; 117(21):5573-81. PubMed ID: 21441462
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prognostic Impact of Serum Heavy/Light Chain Pairs in Patients With Monoclonal Gammopathy of Undetermined Significance and Smoldering Myeloma: Long-Term Results From a Single Institution.
    Magnano L; Fernández de Larrea C; Elena M; Cibeira MT; Tovar N; Aróstegui JI; Pedrosa F; Rosiñol L; Filella X; Yagüe J; Bladé J
    Clin Lymphoma Myeloma Leuk; 2016 Jun; 16(6):e71-7. PubMed ID: 27013181
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Smoldering multiple myeloma 40 years later: a story of unintended disease.
    Yavorkovsky LL
    Expert Rev Hematol; 2021 Feb; 14(2):149-153. PubMed ID: 33430658
    [No Abstract]   [Full Text] [Related]  

  • 18. MGUS and Smoldering Multiple Myeloma: Diagnosis and Epidemiology.
    Mateos MV; Landgren O
    Cancer Treat Res; 2016; 169():3-12. PubMed ID: 27696254
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Smoldering multiple myeloma current treatment algorithms.
    Rajkumar SV; Kumar S; Lonial S; Mateos MV
    Blood Cancer J; 2022 Sep; 12(9):129. PubMed ID: 36064707
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Management of monoclonal gammopathy of undetermined significance (MGUS) and smoldering multiple myeloma (SMM).
    Kyle RA; Rajkumar SV
    Oncology (Williston Park); 2011 Jun; 25(7):578-86. PubMed ID: 21888255
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 14.